CLINICAL STUDIES OF COCAINE TOLERANCE, SENSITIZATION AND WITHDRAWAL

可卡因耐受性、致敏性和戒断的临床研究

• 批准号: 6201631
• 负责人: Reese T. Jones
• 金额: $ 40.85万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-08-01 至 2000-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6201631
• 关键词: behavioral /social science research tag; behavioral habituation /sensitization; clinical research; clinical trials; cocaine; dopamine receptor; drug abuse chemotherapy; drug addiction antagonist; drug habituation; drug tolerance; drug withdrawal; human subject; human therapy evaluation; outcomes research; pharmacokinetics; phenylethylamines; relapse /recurrence; self medication

This component of the proposed SPIRCAP describes two specific aims: 1. To screen clinically available agents that interfere with the acute neurochemical and behavioral responses to cocaine in behavioral, microdialysis and self-administration paradigms. Promising functional cocaine antagonists identified would subsequently be evaluated in human laboratory studies. 2. To screen clinically available pharmacotherapies that interfere with the sensitized response to repeated cocaine administration. In abstinent patients, such pharmacotherapies may protect against relapse to dependence by preventing a single episode of cocaine abuse from producing and especially intense subjective response.

拟议的SPIRCAP的这一组成部分描述了两个具体目标：1。 到 筛选临床上可用的药物，干扰急性 可卡因的神经化学和行为反应， 微透析和自我管理模式。 有前途的功能 随后将在人体中评价所鉴定的可卡因拮抗剂 实验室研究2. 筛选临床可用的药物治疗 干扰对重复可卡因的敏感反应 局 在禁欲患者中，这种药物治疗可以保护 通过预防可卡因的单次发作来防止依赖复发 产生特别强烈的主观反应。